Research programme: HIV infections - OSI Pharmaceuticals/Takeda
Alternative Names: HIV infections research programme - OSI Pharmaceuticals/TakedaLatest Information Update: 16 Jan 2019
At a glance
- Originator OSI Pharmaceuticals; Shire Pharmaceuticals Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
- 16 Mar 1999 New profile